Arrhythmogenic Cardiomyopathy
Cardiovascular·MeSH: Arrhythmogenic Right Ventricular Dysplasia
Prevalence
30.0 / 100K
2 drugs in development·2 companies·4 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| rp-a601 | Rocket Pharmaceuticals Inc. (RCKT) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| lx2020 | Lexeo Therapeutics, Inc. (LXEO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Arrhythmogenic Cardiomyopathy?
BioSniper tracks 2 drugs in development for Arrhythmogenic Cardiomyopathy across 2 companies.
How many clinical trials target Arrhythmogenic Cardiomyopathy?
There are 4 clinical trials targeting Arrhythmogenic Cardiomyopathy tracked by BioSniper.
What is the prevalence of Arrhythmogenic Cardiomyopathy?
The estimated prevalence of Arrhythmogenic Cardiomyopathy is approximately 30.0 per 100,000 population.
Deep-dive into Arrhythmogenic Cardiomyopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis